A Study to Evaluate the Clinical and Microbial Efficacy of 0.6 percent ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.

Trial Profile

A Study to Evaluate the Clinical and Microbial Efficacy of 0.6 percent ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2013

At a glance

  • Drugs Besifloxacin (Primary)
  • Indications Bacterial infections; Conjunctivitis; Haemophilus infections; Infectious conjunctivitis; Pneumococcal infections
  • Focus Therapeutic Use
  • Sponsors Bausch & Lomb
  • Most Recent Events

    • 01 Mar 2009 Primary endpoint 'Clinical response' has been met.
    • 01 Mar 2009 Primary endpoint 'Bacteriological eradication' has been met.
    • 12 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top